REG-4basebio Plc: Strategic Advisory Board & Appointment of Director

4BasebioAnnouncement

08/08/2024 15:45

 

8 August 2024


 

 

 

 

 

4basebio PLC

("4basebio" or the "Company")

 

Strategic Advisory Board Formation

Appointment of Director

 

Cambridge, UK, 8th August 2024 - 4basebio PLC (AIM: 4BB), an innovation-led
provider of novel synthetic DNA products and a non-viral, thermostable nucleic
acid delivery platform announces the formation of a Strategic Advisory Board
and the appointment of Dr Amy Walker, the Vice President of Research and
Business Development to the Board of Directors of the Company as Chief
Operating Officer.

Strategic Advisory Board

Effective from 1 July 2024, the Company formed a Strategic Advisory Board
(“SAB”), with the purpose of offering the Company’s leadership team
valuable advice and industry insight spanning technical, operational,
commercial and strategic matters as well as supporting the Company in the
realisation of its growth goals and objectives.

The SAB advisers are engaged for an initial period of 12 months from its
formation and will meet with the leadership team periodically. The SAB
comprises the following experts:

Bertrand Coissac, CEO at Twogene: Mr. Coissac has extensive experience in the
life science industry with a focus on cell and gene therapy manufacturing.
Before co-founding and leading Twogene, Mr. Coissac was Vice President of
Corporate Development at Polyplus which was successfully acquired by Sartorius
in July 2023.

Lawrence Pitcher, VP at Catalent Pharma Solutions: Mr. Pitcher is currently
the Vice President and General Manager, Maryland Gene Therapy Sites at
Catalent Pharma Solutions. He brings significant operational and business
experience from his current Catalent role and previous roles at Thermo Fisher
Scientific where he was most recently the General Manager of the Advance
Therapies business.

Deborah Barbara, Former Vice President at Maravai Life Sciences:  Ms. Barbara
has over 30 years of life science industry experience in a variety of
strategic business and corporate development roles, most recently as Vice
President of Strategy and Corporate Development for Maravai Life Sciences.
Prior to joining Maravai, Ms. Barbara was General Manager of Nucleic Acid
Therapeutics business for Thermo Fisher Scientific.

Appointment of Director

In addition to the above, the Company announces the appointment of Dr Amy
Walker as Chief Operating Officer of the Company.

Dr Walker joined 4basebio in November 2020 and has served as the Vice
President of Research and Business Development at the Company. Dr Walker has a
background in molecular biology and gene editing technologies, along with
associated nucleic acid nanoparticle delivery platforms. She holds a PhD from
UCL Institute of Child Health and was awarded the prestigious Bogue
Fellowship, conducting part of her doctoral studies at both University of
British Colombia and McGill University, Montreal. Dr Walker has many years
scientific and commercial experience in life sciences, has published
scientific papers and is named inventor on numerous multidisciplinary patents.
She currently holds non-executive director Board positions on two other high
growth healthcare companies.

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the
following information is disclosed in respect of Dr Amy Jo Walker (aged 31): 

 

 Current Directorships                                        
 Heqet Therapeutics S.r.l. Neomatrix Biotechnologies S.r.l    

 

 Previous Directorships held in the past five years  
 None                                                

 

Dr Walker holds 51,506 ordinary shares equating to approximately 0.4 per cent.
in the Company, and 42,128 options over new ordinary shares in the Company.

There is no further information regarding Dr Walker required to be disclosed
under the AIM Rules. 

Dr Heikki Lanckriet, CEO at of 4basebio, commented:  “The adoption of
synthetic DNA is rapidly increasing among cell and gene therapy innovators,
with our technology now being utilized in several clinical programs. As we
advance our commercial development, the combined expertise of Bertrand, Larry,
and Deb in the life sciences and advanced therapies markets will be invaluable
to 4basebio. We look forward to collaborating with this team to drive our
company's success.

“Alongside the formation of the SAB, the Company has reached a new milestone
in appointing Amy as its first Chief Operating Officer underlining its rapid
growth.  Amy has been instrumental in that growth and I am delighted to
welcome her to the Board of Directors.”

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 as amended by regulation 11 of the market abuse
(amendment) (EU Exit) regulations 2019/310.

For further enquiries, please contact:

 4basebio PLC Heikki Lanckriet                                                         +44 (0)12 2396 7943  
 Nominated Adviser     Cairn Financial Advisers LLP Jo Tuner / Sandy Jamieson          +44 (0)20 7213 0880  
 Broker   Cavendish Capital Markets Limited Geoff Nash / Charlie Beeson / Nigel Birks  +44 (0)20 7220 0500  
 Lionsgate Communications (Media Enquiries) Jonathan Charles                           +44 (0)77 91892509   

 

 

Notes to Editors

 

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused
on accelerating the development of advanced therapy medicinal products (ATMPs)
through its high-performance synthetic DNA products and non-viral, cell
targeting nucleic acid delivery platform. The Company’s objective is to
become a market leader in the manufacture and supply of high-quality synthetic
DNA products for research, therapeutic and pharmacological use as well as
development of target specific non-viral vectors for the efficient delivery of
payloads in patients.

Forward-looking statements

This announcement may contain certain statements about the future outlook for
4basebio.  Although the directors believe their expectations are based on
reasonable assumptions, any statements about future outlook may be influenced
by factors that could cause actual outcomes and results to be materially
different.

 



Copyright (c) 2024 PR Newswire Association,LLC. All Rights Reserved